<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348045</url>
  </required_header>
  <id_info>
    <org_study_id>MAZEPPA D19-02</org_study_id>
    <nct_id>NCT04348045</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients</brief_title>
  <acronym>D19-02</acronym>
  <official_title>MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance&#xD;
      therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease&#xD;
      controlled after 4 months of mFOLFIRINOX chemotherapy as following:&#xD;
&#xD;
      Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile&#xD;
      and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus&#xD;
      FOLFIRI Arm C.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Searching for efficient maintenance therapies in metastatic PDAC patients whose disease has&#xD;
      been controlled using an induction chemotherapy is crucial for two main reasons:&#xD;
&#xD;
        1. Patients may stop IV toxic chemotherapy while their tumor remains under control.&#xD;
           Although up to 70% of PDAC patients achieve tumor control when treated during induction&#xD;
           with mFOLFIRINOX, toxicity of this regimen, particularly neuropathy and fatigue, remains&#xD;
           a key concern.&#xD;
&#xD;
        2. Tumor control may be extended, which might improve quality of life (QoL) and survival.&#xD;
&#xD;
      Patients are included in MAZEPPA study based on the genetic profile of their tumor.&#xD;
&#xD;
        -  If a BRCA gene mutation is present in the tumor, treatment with the drug olaparib will&#xD;
           be proposed (arm A), regardless of the status of the other genes analyzed.&#xD;
&#xD;
        -  In the absence of a mutation in the BRCA gene and in the presence of a mutation in the&#xD;
           KRAS gene, a treatment combining immunotherapy and targeted therapy (durvalumab and&#xD;
           selumetinib - Arm B) or chemotherapy by FOLFIRI (arm C) will be proposed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ARM A - Progression free survival (PFS)</measure>
    <time_frame>at 4 months</time_frame>
    <description>PFS rate at 4 months is defined by the number of patients alive at 4 months from inclusion without PD divided by the total number of patients evaluable at 4 months (dead during 4 months or alive at 4 months with a progressive status available).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ARM B/ C - PFS</measure>
    <time_frame>Assessed up to 36 months</time_frame>
    <description>PFS is defined as time from randomization into arm B/C to the date of first documented PD RECIST 1.1 and/or iRECIST for arm B and PD RECIST1.1 for arm C or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Measured at 16 weeks of maintenance therapy.</time_frame>
    <description>DCR is the percentage of patients who achieve CR, PR, or SD to study treatment (according to RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Assessed up to 36 months</time_frame>
    <description>ORR is the number of patients with a best overall response of CR or PR divided by the number of all treated (at least 1 dose of study treatment) patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Assessed up to 36 months</time_frame>
    <description>OS is the time between the date of inclusion into Arm A or Arms B/C and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Assessed up to 36 months</time_frame>
    <description>All grade and severe toxicities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HRQoL score definitive deterioration (TUDD)</measure>
    <time_frame>At baseline, at every 2 months during treatment, and at the end of treatment visit. Assessed up to 36 months</time_frame>
    <description>TUDD is defined as the time interval between inclusion into Arm A and randomization into Arms B/C and the first occurrence of a decrease in QLQ-C30 score for dimension ⩾5 points compared to baseline HRQoL score without any further improvement in QoL score ⩾5 points or any further available QoL data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">307</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>ARM A - olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B - durvalumab plus selumetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.&#xD;
Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,&#xD;
Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C - FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A - Olaparib</intervention_name>
    <description>300 mg orally twice daily, for a total daily dose of 600mg&#xD;
Study treatment can be dose-reduced to :&#xD;
First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued.</description>
    <arm_group_label>ARM A - olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM B - durvalumab plus selumetinib</intervention_name>
    <description>Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily&#xD;
Study treatment can be dose-reduced to :&#xD;
Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily</description>
    <arm_group_label>ARM B - durvalumab plus selumetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARM C FOLFIRI</intervention_name>
    <description>FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2</description>
    <arm_group_label>ARM C - FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent,&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Body weight &gt;30 kg,&#xD;
&#xD;
          4. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up,&#xD;
&#xD;
          5. Life expectancy of at least 4 months,&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1,&#xD;
&#xD;
          7. Pathologically confirmed pancreatic adenocarcinoma with distant metastases (stage IV&#xD;
             disease),&#xD;
&#xD;
          8. No prior therapy for metastatic disease other than mFOLFIRINOX (in case of previous&#xD;
             adjuvant therapy, the interval between the end of adjuvant chemotherapy and relapse&#xD;
             must be &gt;6 months),&#xD;
&#xD;
          9. Stability or tumor response (Response evaluation criteria in solid tumors [RECIST]&#xD;
             1.1) after 4 months of mFOLFIRINOX (8 cycles) for metastatic disease,&#xD;
&#xD;
         10. Have tissue from archival tissue sample from surgery or biopsy identified and&#xD;
             confirmed as available for study&#xD;
&#xD;
         11. Availability of tumor somatic genetic analyses data, performed during the first 4&#xD;
             months of mFOLFIRINOX (specific informed consent),&#xD;
&#xD;
         12. In case of germinal BRCA gene mutation identified before inclusion the patient can be&#xD;
             included until olaparib receives a marketing authorization for the treatment&#xD;
             indication of the patients in the study and the treatment is available in the retail&#xD;
             pharmacy; it will be prescribed according to the summary product characteristics&#xD;
             (SmPC),&#xD;
&#xD;
         13. At least one measurable or evaluable lesion as assessed by CT-scan or MRI according to&#xD;
             RECIST 1.1 and feasibility of repeated radiological assessments,&#xD;
&#xD;
         14. Normal organ and bone marrow function prior to administration of study treatment as&#xD;
             defined below:&#xD;
&#xD;
               -  Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days,&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L,&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L,&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN),&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x&#xD;
                  institutional ULN unless liver metastases are present in which case&#xD;
&#xD;
                  ≤ 5x ULN,&#xD;
&#xD;
               -  Creatinine clearance (CrCl) ≥ 50 mL/min estimated using the Cockcroft-Gault&#xD;
                  equation, Estimated CrCl =(140-age [years]) x weight (kg) (x F)a serum creatinine&#xD;
                  (mg/dL) x 72 a F=0.85 for females and F=1 for males.&#xD;
&#xD;
         15. Absence of known dihydropyrimidine dehydrogenase (DPD) deficiency,&#xD;
&#xD;
         16. Female patients must be surgically sterile, or be post-menopausal, or have negative&#xD;
             serum pregnancy test if pre-menopausal at inclusion and must commit to using reliable&#xD;
             and appropriate methods of contraception during the study and during at least 6 months&#xD;
             after the end of studytreatment (when applicable).&#xD;
&#xD;
             Women will be considered post-menopausal if they have been amenorrhoeic for 12 months&#xD;
             without an alternative medical cause. The following age-specific requirements apply:&#xD;
&#xD;
               -  Women &lt; 50 years of age would be considered post-menopausal if they have been&#xD;
                  amenorrhoeic for 12 months or more following cessation of exogenous hormonal&#xD;
                  treatments and if they have luteinizing hormone (LH) and follicle-stimulating&#xD;
                  hormone (FSH) levels in the postmenopausal range for the institution or underwent&#xD;
                  surgical sterilization (bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
               -  Women ≥ 50 years of age would be considered post-menopausal if they have been&#xD;
                  amenorrhoeic for 12 months or more following cessation of all exogenous hormonal&#xD;
                  treatments, had radiation-induced menopause with last menses &gt; 1 year ago, had&#xD;
                  chemotherapy-induced menopause with last menses &gt; 1 year ago, or underwent&#xD;
                  surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or&#xD;
                  hysterectomy). All female patients with reproductive potential must have a&#xD;
                  negative pregnancy test (beta human chorionic gonadotropin [β-HCG]) within 72&#xD;
                  hours prior to starting the protocol treatment. Breastfeeding is not allowed.&#xD;
                  Male patients must agree to use effective contraception in addition to having&#xD;
                  their partner use a contraceptive method as well during the trial and during at&#xD;
                  least 6 months after the end of the study treatment. Men and women with childhood&#xD;
                  potential are required to use adequate birth control during the study,&#xD;
&#xD;
         17. Registration in a national health care system (PUMa; Couverture Maladie Universelle&#xD;
             included).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histology other than PDAC&#xD;
&#xD;
          2. Toxicities after mFOLFIRINOX treatment not resolved to ≥ grade 1 prior to maintenance&#xD;
             treatment, except for oxaliplatin induced neuropathy, alopecia, or grade ≥ 2 are&#xD;
             permitted&#xD;
&#xD;
          3. Patients with known brain metastases at inclusion,&#xD;
&#xD;
          4. Enrollment in another therapeutic trial&#xD;
&#xD;
          5. Evidence of interstitial lung disease, any active non-infectious pneumonitis, or known&#xD;
             active infection including active tuberculosis&#xD;
&#xD;
          6. Hepatitis B virus (HBV; known positive HBV surface antigen (HbsAg) result), hepatitis&#xD;
             C virus (HCV), or human immunodeficiency virus (positive HIV ½ antibodies).&#xD;
&#xD;
          7. Active uncontrolled infection, current unstable, or uncompensated respiratory or&#xD;
             cardiac conditions, or active digestive hemorrhages less than 3 months,&#xD;
&#xD;
          8. Patient has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the study,&#xD;
&#xD;
          9. Live vaccine administration within 30 days prior to the first dose of study treatment,&#xD;
&#xD;
         10. Treatment with any other investigational medicinal product within 28 days prior to&#xD;
             study entry,&#xD;
&#xD;
         11. Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years&#xD;
             except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer&#xD;
             of the cervix, ductal carcinoma in situ (DCIS), and stage 1, grade 1 endometrial&#xD;
             carcinoma,&#xD;
&#xD;
         12. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, acute&#xD;
             coronary syndrome within 6 months prior to starting treatment, prior or current&#xD;
             cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, interstitial lung&#xD;
             disease, serious chronic gastrointestinal conditions associated with diarrhea, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirement, substantially increase risk of incurring AEs or compromise the ability of&#xD;
             the patient to give written informed consent,&#xD;
&#xD;
         13. Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible&#xD;
             cardiac conditions, as judged by the Investigator or patients with congenital long QT&#xD;
             syndrome. Mean corrected QT interval (QTc) for heart rate using the QTcF formula ≥&#xD;
             must be &lt;470 ms,&#xD;
&#xD;
         14. Pregnancy/lactation,&#xD;
&#xD;
         15. Uncontrolled massive pleural effusion or massive ascites,&#xD;
&#xD;
         16. Tutelage or guardianship.&#xD;
&#xD;
        Arm A: Specific exclusion criteria for patients with the BRCAness profile in order to&#xD;
        receive olaparib&#xD;
&#xD;
          1. Myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of&#xD;
             myelodysplastic syndrome (MDS)/ DS)/acute myeloid leukemia (AML),&#xD;
&#xD;
          2. Unable to swallow orally administered medication and gastrointestinal disorders likely&#xD;
             to interfere with absorption of the study medication,&#xD;
&#xD;
          3. Any previous treatment with PARP inhibitor, including olaparib,&#xD;
&#xD;
          4. Concomitant use of known strong cytochrome P450, family 3, subfamily A (CYP3A)&#xD;
             inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors&#xD;
             boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir,&#xD;
             telaprevir) or moderate CYP3A inhibitors. The required washout period prior to&#xD;
             starting olaparib is 2 weeks,&#xD;
&#xD;
          5. Concomitant use of known strong or moderate CYP3A inducers.&#xD;
&#xD;
          6. Major surgery within 2 weeks of starting study treatment and patients must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
          7. Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT),&#xD;
&#xD;
          8. Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable outside of 28 days prior to study&#xD;
             treatment,&#xD;
&#xD;
          9. Known hypersensitivity to the excipients of the olaparib&#xD;
&#xD;
        Arm B/C: Specific criteria for patients without the BRCAness profile and with KRAS mutation&#xD;
        in order to receive durvalumab:&#xD;
&#xD;
          1. Prior treatment with any of the following immune checkpoint inhibitor:&#xD;
&#xD;
             anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T lymphocyte antigen 4 (CTLA-4)&#xD;
             antibody,&#xD;
&#xD;
          2. Active autoimmune disease that has required systemic treatment in the past 2 years;&#xD;
             replacement therapy is considered a form of systemic treatment and is not a criterion&#xD;
             of exclusion,&#xD;
&#xD;
          3. Any systemic steroid therapy whatever the duration of this corticotherapy,&#xD;
&#xD;
          4. Active or prior documented autoimmune or inflammatory disorders&#xD;
&#xD;
        Arm B/C: Specific exclusion criteria for patients without BRCAness profile and with&#xD;
        KRAS-mutated tumors in order to receive selumetinib:&#xD;
&#xD;
          1. Cardiac conditions&#xD;
&#xD;
          2. Documented antecedent history of retinopathy or retinal disorders as known&#xD;
             ophthalmologic conditions&#xD;
&#xD;
          3. Patients with any other significant abnormality on ophthalmic examination (performed&#xD;
             by an ophthalmologist) should be discussed for potential ineligibility&#xD;
&#xD;
          4. The last palliative radiotherapy seance within 7 days of the first dose of study&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal HAMMEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal HAMMEL, MD</last_name>
    <phone>01 40 29 85 00</phone>
    <email>pascal.hammel@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Line GARCIA LARNICOL, MD</last_name>
    <phone>01 40 29 85 00</phone>
    <email>marie-line.garcia-larnicol@gercor.com.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence TOULLEC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clémence TOULLEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe BORG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BORG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric LECAILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cédric LECAILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie PARZY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie PARZY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia HENTIC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivia HENTIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHPSO Site de Creil</name>
      <address>
        <city>Creil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CAROLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine DROUILLARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine DROUILLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaël ROTH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaël ROTH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Franco-Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène MARIJON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hélène MARIJON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony TURPIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony TURPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle DE LA FOUCHARDIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle DE LA FOUCHARDIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloé VERNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chloé VERNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis PERET VERGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Denis PERET VERGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtitia DAHAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laëtitia DAHAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves RINALDI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves RINALDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marine GILABERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marine GILABERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano KIM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefano KIM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier DUBREUIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien TAIEB, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien TAIEB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Baptiste BACHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Baptiste BACHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle TROUILLOUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle TROUILLOUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Site de Saint Herblain</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique HIRET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Véronique HIRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher BEN ABDELGHANI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meher BEN ABDELGHANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse IUCT Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosine GUIMBAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry LECOMTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry LECOMTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCAness status</keyword>
  <keyword>KRAS somatic status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

